"rationale","id","description","uuid:ID","name","instanceType","label"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyDesign_1","The main design for the study","da7c14fb-50d4-4ba0-ba26-35c702074026","Study Design 1","StudyDesign",""
